Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
RVNC

RVNC - Revance Therapeutics Inc Stock Price, Fair Value and News

$3.65 
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

RVNC Price Action

RVNC RSI Chart

RVNC Valuation

RVNC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RVNC Fundamentals

RVNC Revenue

RVNC Earnings

RVNC Profitability

RVNC Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024240.2M251.2M256.9M0
2023153.1M179.1M204.2M234.0M
202289.8M99.3M108.6M132.6M
202128.6M47.1M63.0M77.8M
20204.1M7.9M11.6M15.3M
20194.3M4.8M5.1M413.0K
20182.4M3.1M4.0M3.7M
20171.2M1.2M963.0K1.7M
2016502.0K777.0K1.0M1.2M
2015252.0K226.0K219.0K219.0K
2014700.0K700.0K617.0K383.0K
2013266.8K383.5K500.3K617.0K
2012000150.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Revance Therapeutics Inc

RVNC
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
 CEO
 WEBSITErevance.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES534